What is Leerink Partnrs’ Forecast for ELDN Q1 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.28) per share for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.29) EPS.

Separately, Guggenheim began coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 price target for the company.

Eledon Pharmaceuticals Price Performance

ELDN stock opened at $3.47 on Tuesday. Eledon Pharmaceuticals has a 1-year low of $1.52 and a 1-year high of $5.54. The business has a 50-day moving average price of $4.15 and a 200 day moving average price of $3.89. The company has a market capitalization of $207.29 million, a P/E ratio of -1.73 and a beta of 0.80.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its earnings results on Thursday, March 20th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same quarter last year, the company earned ($1.00) earnings per share.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. acquired a new position in Eledon Pharmaceuticals during the 4th quarter valued at approximately $14,693,000. Sphera Funds Management LTD. grew its holdings in shares of Eledon Pharmaceuticals by 96.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company’s stock valued at $10,513,000 after buying an additional 1,254,298 shares during the last quarter. First Light Asset Management LLC acquired a new position in shares of Eledon Pharmaceuticals in the 4th quarter valued at $9,595,000. Blue Owl Capital Holdings LP purchased a new position in Eledon Pharmaceuticals in the 4th quarter worth $8,075,000. Finally, Woodline Partners LP lifted its position in Eledon Pharmaceuticals by 98.3% during the 4th quarter. Woodline Partners LP now owns 1,671,822 shares of the company’s stock worth $6,888,000 after acquiring an additional 828,930 shares during the period. 56.77% of the stock is owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).